Phase II/III Double-Blind Study Evaluating Safety and Immunogenicity of a Single Intramuscular Booster Dose of the Recombinant SARS-CoV-2 Vaccine “Patria” (AVX/COVID-12) Using an Active Newcastle Disease Viral Vector (NDV) during the Omicron Outbreak in Healthy Adults with Elevated Baseline Antibody Titers from Prior COVID-19 and/or SARS-CoV-2 Vaccination
Abstract Background The urgent need for safe, effective, and economical coronavirus disease 2019 (COVID-19) vaccines, especially for booster campaigns targeting vulnerable populations, prompted the development of the AVX/COVID-12 vaccine candidate. AVX/COVD-12 is based in a Newcastle disease virus La Sota (NDV-LaSota) recombinant viral vector. This vaccine expresses a stabilized version of the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), specifically the ancestral Wuhan strain. The study aimed to assess its safety, immunogenicity, and potential efficacy as an anti-COVID-19 booster vaccine.Methods In a phase II/III clinical trial conducted from November 9, 2022, to September 11, 2023, a total of 4,056 volunteers were enrolled. Participants received an intramuscular booster dose of either AVX/COVID-12 or AZ/ChAdOx-1-S vaccines. Safety, immunogenicity, and potential efficacy were assessed through various measures, including neutralizing antibody titers, interferon (IFN)-γ-producing CD4+ T cells, and CD8+ T cells. The evaluation also involved immunobridging, utilizing the AZ/ChAdOx-1-S vaccine as an active comparator, and monitoring the incidence of COVID-19 cases.Findings The AVX/COVID-12 vaccine induced neutralizing antibodies against both the ancestral SARS-CoV-2 and the BA.2 and BA.5 Omicron variants. The geometric mean ratio of neutralizing antibody titers between individuals immunized with the AVX/COVID-12 vaccine and those with the AZ/ChAdOx-1-S vaccine at 14 days is 0.96, with a confidence interval (CI) of 0.85-1.06. The outcome aligns with the non-inferiority criterion recommended by the World Health Organization (WHO), indicating a lower limit of the CI greater than or equal to 0.67. Induction of IFN-γ-producing CD8+ T cells at day 14 post-immunization was exclusively observed in the AVX/COVID-12 group. Finally, a trend suggested a potentially lower incidence of COVID-19 cases in AVX/COVID-12 boosted volunteers compared to AZ/ChAdOx-1-S recipients.Conclusion The AVX/COVID-12 vaccine proved safe, well-tolerated, and immunogenic. AVX/COVID-12 meets the WHO non-inferiority standard compared to AZ/ChAdOx-1-S. These results strongly advocate for AVX/COVID-12 as a viable booster dose, supporting its utilization in the population..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 16. Feb. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2024.02.11.24302530 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI042512883 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI042512883 | ||
| 003 | DE-627 | ||
| 005 | 20240217134605.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240215s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2024.02.11.24302530 |2 doi | |
| 035 | |a (DE-627)XBI042512883 | ||
| 035 | |a (biorXiv)10.1101/2024.02.11.24302530 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a López-Macías, Constantino |e verfasserin |0 (orcid)0000-0003-0530-492X |4 aut | |
| 245 | 1 | 0 | |a Phase II/III Double-Blind Study Evaluating Safety and Immunogenicity of a Single Intramuscular Booster Dose of the Recombinant SARS-CoV-2 Vaccine “Patria” (AVX/COVID-12) Using an Active Newcastle Disease Viral Vector (NDV) during the Omicron Outbreak in Healthy Adults with Elevated Baseline Antibody Titers from Prior COVID-19 and/or SARS-CoV-2 Vaccination |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background The urgent need for safe, effective, and economical coronavirus disease 2019 (COVID-19) vaccines, especially for booster campaigns targeting vulnerable populations, prompted the development of the AVX/COVID-12 vaccine candidate. AVX/COVD-12 is based in a Newcastle disease virus La Sota (NDV-LaSota) recombinant viral vector. This vaccine expresses a stabilized version of the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), specifically the ancestral Wuhan strain. The study aimed to assess its safety, immunogenicity, and potential efficacy as an anti-COVID-19 booster vaccine.Methods In a phase II/III clinical trial conducted from November 9, 2022, to September 11, 2023, a total of 4,056 volunteers were enrolled. Participants received an intramuscular booster dose of either AVX/COVID-12 or AZ/ChAdOx-1-S vaccines. Safety, immunogenicity, and potential efficacy were assessed through various measures, including neutralizing antibody titers, interferon (IFN)-γ-producing CD4+ T cells, and CD8+ T cells. The evaluation also involved immunobridging, utilizing the AZ/ChAdOx-1-S vaccine as an active comparator, and monitoring the incidence of COVID-19 cases.Findings The AVX/COVID-12 vaccine induced neutralizing antibodies against both the ancestral SARS-CoV-2 and the BA.2 and BA.5 Omicron variants. The geometric mean ratio of neutralizing antibody titers between individuals immunized with the AVX/COVID-12 vaccine and those with the AZ/ChAdOx-1-S vaccine at 14 days is 0.96, with a confidence interval (CI) of 0.85-1.06. The outcome aligns with the non-inferiority criterion recommended by the World Health Organization (WHO), indicating a lower limit of the CI greater than or equal to 0.67. Induction of IFN-γ-producing CD8+ T cells at day 14 post-immunization was exclusively observed in the AVX/COVID-12 group. Finally, a trend suggested a potentially lower incidence of COVID-19 cases in AVX/COVID-12 boosted volunteers compared to AZ/ChAdOx-1-S recipients.Conclusion The AVX/COVID-12 vaccine proved safe, well-tolerated, and immunogenic. AVX/COVID-12 meets the WHO non-inferiority standard compared to AZ/ChAdOx-1-S. These results strongly advocate for AVX/COVID-12 as a viable booster dose, supporting its utilization in the population. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Torres, Martha |0 (orcid)0000-0003-3217-9407 |4 aut | |
| 700 | 1 | |a Armenta-Copca, Brenda |4 aut | |
| 700 | 1 | |a Wacher, Niels H. |0 (orcid)0000-0002-7717-6704 |4 aut | |
| 700 | 1 | |a Galindo-Fraga, Arturo |0 (orcid)0000-0002-2818-1160 |4 aut | |
| 700 | 1 | |a Castro-Castrezana, Laura |0 (orcid)0009-0006-1461-5593 |4 aut | |
| 700 | 1 | |a Colli-Domínguez, Andrea Alicia |4 aut | |
| 700 | 1 | |a Cervantes-Trujano, Edgar |4 aut | |
| 700 | 1 | |a Rucker-Joerg, Isabel Erika |4 aut | |
| 700 | 1 | |a Lozano-Patiño, Fernando |0 (orcid)0000-0001-7998-1339 |4 aut | |
| 700 | 1 | |a Rivera-Alcocer, Juan José |0 (orcid)0009-0003-9297-9139 |4 aut | |
| 700 | 1 | |a Simón-Campos, Abraham |0 (orcid)0000-0001-9630-7792 |4 aut | |
| 700 | 1 | |a Sánchez-Campos, Efrén Alberto |0 (orcid)0000-0002-9284-2541 |4 aut | |
| 700 | 1 | |a Aguirre-Rivero, Rafael |4 aut | |
| 700 | 1 | |a Muñiz-Carvajal, Alejandro José |0 (orcid)0000-0002-1522-4141 |4 aut | |
| 700 | 1 | |a Carpio-Orantes, Luis del |0 (orcid)0000-0003-2436-5744 |4 aut | |
| 700 | 1 | |a Márquez-Díaz, Francisco |4 aut | |
| 700 | 1 | |a Rivera-Hernández, Tania |0 (orcid)0000-0002-3582-9973 |4 aut | |
| 700 | 1 | |a Torres-Flores, Alejandro |0 (orcid)0000-0003-3705-6692 |4 aut | |
| 700 | 1 | |a Ramírez-Martínez, Luis |4 aut | |
| 700 | 1 | |a Paz-De la Rosa, Georgina |0 (orcid)0000-0002-0491-9271 |4 aut | |
| 700 | 1 | |a Rojas-Martínez, Oscar |4 aut | |
| 700 | 1 | |a Suárez-Martínez, Alejandro |4 aut | |
| 700 | 1 | |a Peralta-Sánchez, Gustavo |0 (orcid)0000-0003-1174-8455 |4 aut | |
| 700 | 1 | |a Carranza, Claudia |0 (orcid)0000-0001-6226-6056 |4 aut | |
| 700 | 1 | |a Juárez, Esmeralda |0 (orcid)0000-0001-9036-004X |4 aut | |
| 700 | 1 | |a Zamudio-Meza, Horacio |0 (orcid)0000-0002-8456-2881 |4 aut | |
| 700 | 1 | |a Carreto-Binaghi, Laura E. |0 (orcid)0000-0003-0356-4138 |4 aut | |
| 700 | 1 | |a Viettri, Mercedes |0 (orcid)0000-0002-3290-2952 |4 aut | |
| 700 | 1 | |a Romero-Rodríguez, Damaris |0 (orcid)0000-0003-1936-0279 |4 aut | |
| 700 | 1 | |a Palencia, Andrea |4 aut | |
| 700 | 1 | |a Sarfati-Mizrahi, David |4 aut | |
| 700 | 1 | |a Sun, Weina |0 (orcid)0000-0002-2435-5047 |4 aut | |
| 700 | 1 | |a Chagoya-Cortés, Héctor Elías |0 (orcid)0009-0006-2786-4724 |4 aut | |
| 700 | 1 | |a Castro-Peralta, Felipa |0 (orcid)0000-0003-3982-6259 |4 aut | |
| 700 | 1 | |a Palese, Peter |0 (orcid)0000-0002-0337-5823 |4 aut | |
| 700 | 1 | |a Krammer, Florian |0 (orcid)0000-0003-4121-776X |4 aut | |
| 700 | 1 | |a García-Sastre, Adolfo |0 (orcid)0000-0002-6551-1827 |4 aut | |
| 700 | 1 | |a Lozano-Dubernard, Bernardo |0 (orcid)0009-0009-6430-7080 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 16. Feb. |
| 773 | 1 | 8 | |g year:2024 |g day:16 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2024.02.11.24302530 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 16 |c 02 | ||